06:08:11 EDT Mon 15 Aug 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Avicanna Inc
Symbol AVCN
Shares Issued 41,271,574
Close 2021-09-24 C$ 0.97
Recent Sedar Documents

Avicanna applies for cannabinoid formulation patent

2021-09-24 09:03 ET - News Release

Mr. Aras Azadian reports

AVICANNA FILES US PATENT APPLICATION FOR A NOVEL CANNABINOID FORMULATION IN REDUCING INCIDENCE OF SEIZURES AND SUDDEN UNEXPECTED DEATH IN EPILEPSY

Avicanna Inc. has filed a provisional patent application with the United States Patent and Trademark Office, entitled "Methods for Reducing or Eliminating Incidence of Seizures and Sudden Unexpected Death in Epilepsy," on the use of a novel cannabinoid formulation.

The research findings originated from the continuing multilevel cannabinoid-based collaboration with leading epilepsy researcher Dr. Peter Carlen at the world-renowned Krembil Research Institute at the University Health Network (UHN). Preliminary electrophysiological studies on seizure induced wild-type mouse cortical slices determined that treatment with the formulation candidate produced significant anti-convulsant effects as compared with treatment with cannabidiol (CBD) or tetrahydrocannabinol (THC) alone. These results, obtained in a well-established in vitro model, suggest that, in addition to anti-convulsant properties, the formulation candidate demonstrates strong potential to treat patients diagnosed with intractable forms of epilepsies and at risk of seizure-induced sudden unexpected death in epilepsy (SUDEP). Further studies on the mechanism of action of the cannabinoids in the formulation candidate confirmed that the cannabinoids acted as selective 5-HT1A (serotonin 1A) receptor agonists similar to established 5-HT1A receptor agonists in seizure-like events.

Aras Azadian, chief executive officer of Avicanna, stated: "Understanding the anti-convulsant properties of our proprietary formulation in seizure disorders is important particularly since this combination drug has potential to reduce the likelihood of seizure-induced sudden death in epilepsy. The exceptional research conducted by Dr. Carlen's team with support from our R&D [research and development] team and the resulting patent submission will be a major driver for guiding our long-term drug and clinical development plans, particularly since its in the area with an existing FDA-approved [Food and Drug Administration] cannabinoid-based drug."

Avicanna intends to conduct in vivo studies in the coming months in order to formalize this provisional application. If granted, this patent application will provide Avicanna with protection on the use of the formulation candidate within a specified ratio of cannabinoids, alone or in combination with other anti-epileptic agents.

About Avicanna Inc.

Avicanna is a commercial-stage Canadian biopharmaceutical company and an established leader in cannabinoid research, development and evidence-based products for the global consumer, medical and pharmaceutical market segments. Avicanna conducts its research in Canada, including its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada, located in the MaRS discovery district, and in collaboration with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform, including advanced R&D and clinical development, which has led to the commercialization of over 20 products across four main market segments.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.